The Emerging Epidemic of Early-Onset Cancer: Global Patterns,Biological Complexity,and Urgent Calls for Action

Abstract

Cancer is often considered a disease of older adults, yet in recent decades an increasing number of people under the age of 50 have been diagnosed with cancer worldwide. According to global data, the most common early-onset cancers include breast, tracheal/bronchus/lung, stomach, and colorectal cancers, followed by thyroid, pancreas, and liver malignancies. These cancers often behave more aggressively than those diagnosed later in life and contribute substantially to premature mortality and disability. Researchers believe that this trend is driven less by hereditary syndromes and more by cumulative environmental and lifestyle exposures beginning early in life. Diets high in ultra-processed foods, reduced physical activity, antibiotic overuse, pollution, psychosocial stress, and disruptions of the gut microbiome have all been implicated as potential contributors. Unlike inherited cancer syndromes, most early-onset cancers are sporadic, arising from complex interactions between modifiable exposures and host biology. Younger patients face unique challenges: they are underrepresented in clinical trials, often lack access to age-appropriate multidisciplinary care, and experience disruptions to education, employment, and family planning. Addressing this growing public health concern requires earlier screening for high-risk groups, investment in adolescent and young adult (AYA)-specific biorepositories and research, and policies that prioritize prevention, equity, and tailored care for younger populations.

Over the past 3 decades, a concerning rise in the incidence of early-onset cancers (EOCs)—defined as malignant neoplasms diagnosed before the age of 50—has been documented across the globe. Initially noted in colorectal cancer, this trend now extends to a broad spectrum of tumors, including those of the breast, bile duct, pancreas, stomach, thyroid, and hematological systems.^1-3

According to the Global Burden of Disease 2019 study, the incidence of EOCs increased by nearly 80% between 1990 and 2019, with more than 3.2 million new cases reported globally in 2019. ¹ The leading EOCs worldwide were breast, tracheal/bronchus/lung, stomach, and colorectal cancers, which together accounted for the highest mortality and disability-adjusted life years (DALYs). ¹ Breast cancer predominates among women, whereas tracheal–bronchus–lung cancers are the leading cause of EOCs mortality in men. ¹

The shift in cancer epidemiology from older to younger populations poses significant clinical, societal, and economic challenges, demanding renewed attention from researchers, clinicians, and policymakers worldwide.^2,4 This epidemiological transition is neither anecdotal nor geographically restricted. In high-, middle-, and low-income settings, cancer registries have captured escalating trends in EOCs incidence. In the United States, for example, the prevalence of colorectal cancer among individuals under 50 has increased markedly since the 1990s. ² Similar increases have been reported for breast, kidney, thyroid, and pancreatic cancers. In Brazil, our recent hospital-based registry analysis, encompassing more than 600 000 cases from 2000 to 2019, identified consistent and often alarming rises in early-onset breast, thyroid, cervical, colorectal, and hematological cancers, particularly among women aged 19-44. ⁵

In South Korea, colorectal cancer incidence among adults under 50 has nearly doubled over the past 2 decades, ⁶ while in China lung/bronchus and liver cancers remain among the leading causes of premature mortality. ⁷ In parts of sub-Saharan Africa, increasing rates of early-onset breast and cervical cancers underscore profound disparities in surveillance and access to care. ⁸ These findings highlight structural and cultural differences in exposures and system readiness. The World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) have emphasized the urgency of strengthening global cancer surveillance and prevention strategies. ⁹

The etiology of EOCs remains complex and multifactorial. While enhanced screening and early detection may partially explain increased diagnoses in certain tumor types (eg, thyroid and breast cancers), current evidence suggests a genuine rise in incidence unrelated to diagnostic advances alone.^2,10

Screening disparities further compound this burden. Colonoscopy and mammography are widely available in high-income countries, but access remains limited in many LMICs, leading to later-stage diagnosis and poorer outcomes. ¹¹ In addition, most guidelines, designed for older adults, may fail to capture high-risk younger populations.

The exposome—the totality of environmental exposures accumulated across the life course—provides a unifying framework to investigate these trends. It includes general external factors (socioeconomic status, education, psychosocial stress), specific external exposures (pollutants, diet, infections, lifestyle behaviors), and internal processes (metabolism, hormones, inflammation, microbiome). ¹² From the widespread consumption of ultra-processed foods and sugar-sweetened beverages to sedentary lifestyles, antibiotic overuse, and microbiome dysregulation, the constellation of exposures experienced from childhood onward may be fueling this new cancer epidemic.^2,10

Mechanistic insights illustrate these pathways: gut microbiome dysbiosis promotes chronic inflammation, impaired immune surveillance, and carcinogenic metabolites^13,14; diets rich in ultra-processed foods and sugary drinks contribute to obesity, insulin resistance, and systemic inflammation ¹⁵ ; and early-life antibiotic exposure disrupts protective taxa, fostering pro-carcinogenic environments. ¹³ Food insecurity further exacerbates the problem by driving reliance on calorie-dense, nutrient-poor diets, which are strongly associated with metabolic dysfunction and increased cancer risk. ¹⁶

Of particular concern is the observation that most EOCs arise sporadically rather than from hereditary syndromes, despite presenting at younger ages. ¹⁰ While hereditary conditions such as Lynch syndrome or BRCA mutations account for fewer than 10% of cases, the majority result from complex interactions between polygenic susceptibility and environmental or lifestyle exposures, highlighting the importance of identifying modifiable risk factors. Beyond their etiology, many EOCs display more aggressive biology and poorer outcomes compared to their later-onset counterparts. Despite receiving more intensive therapies, younger patients frequently endure greater toxicity without proportional survival gains. These clinical challenges underscore the need to refine treatment paradigms and develop age-adapted strategies tailored to younger populations. ¹⁰

The adolescent and young adult (AYA) population is particularly vulnerable in this scenario. As highlighted by the ESMO-SIOPE joint working group, AYA patients are often caught between pediatric and adult oncology systems, lacking access to age-appropriate, multidisciplinary care and dedicated clinical trials. ¹⁷ They are underrepresented in early-phase studies, ¹⁷ and disparities in fertility preservation and psychosocial support persist, particularly in LMICs. ¹⁸

To address the EOCs epidemic, a coordinated and global research agenda is urgently needed. Priority areas include establishing lifecourse cohorts, international data sharing, and AYA-specific biorepositories, especially in LMICs where surveillance gaps are greatest. ¹⁹

Molecular Pathological Epidemiology (MPE) offers a promising transdisciplinary framework to explore gene–environment interactions and identify predictive biomarkers.^2,10 Global collaborative consortia are essential to accelerate discoveries and translate them into prevention and policy.

In addition, Artificial Intelligence (AI) holds promise to enhance early detection, risk stratification, and resource allocation. AI-assisted algorithms have demonstrated potential to improve diagnostic accuracy and reduce disparities in resource-limited settings. ²⁰

Early-onset cancers is no longer an anomaly—it is a defining feature of contemporary oncology. As the demographic profile of cancer patients shifts, so too must our research questions, clinical practices, and public health strategies. Concrete priorities include lowering screening ages for high-risk populations, ²¹ investing in AYA-specific biorepositories, and incorporating EOCs into national control plans. Addressing social determinants such as food insecurity is equally critical to reduce disparities.

Global collaboration is imperative: without timely investment in prevention, surveillance, and tailored care, health systems risk being overwhelmed by a preventable burden. Conversely, early, coordinated action offers the opportunity to transform this emerging crisis into progress for cancer control across generations.